Oral contraceptives may influence the risk of certain cancers. As part of the AHRQ Evidence
Report, Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer, we conducted …

Mortality from ovarian cancer may be dramatically reduced with the implementation of
attainable prevention strategies. The new understanding of the cells of origin and the …

Background There is substantial variability in cancer risk in women who have inherited a
BRCA1 or BRCA2 (BRCA1/2) mutation. Numerous factors have been hypothesized to …

Abstract The 1st International Consensus Conference for Breast Cancer in Young Women
(BCY1) took place in November 2012, in Dublin, Ireland organized by the European School …

Abstract The 2nd International Consensus Conference for Breast Cancer in Young Women
(BCY2) took place in November 2014, in Dublin, Ireland organized by the European School …

Purpose Risk-reducing salpingo-oophorectomy (RRSO) lowers mortality from ovarian/tubal
and breast cancers among BRCA1/2 mutation carriers. Uncertainties persist regarding …

Approximately, 7% of all breast cancers (BC) and 11–15% of ovarian cancers (OC) are
associated with inherited predisposition, mainly related to germline mutations in high …

Purpose BRCA mutation carriers have an increased risk of developing breast or ovarian
cancer. Oral contraception (OC) is known to increase breast cancer and reduce ovarian …

Breast cancer is the most commonly occurring cancer in women, the second most frequent
cancer overall, and it causes the greatest number of cancer-related deaths among women …

BACKGROUND Increasing numbers of BReast CAncer (BRCA) 1 or 2 pathogenic variant
(PV) carriers, who have an inherited predisposition to breast and ovarian cancer, are being …